外周血炎性标志物在甲状腺癌中的应用进展  

Application of peripheral blood inflammatory markers in thyroid cancer

作　　者：周春燕[1] 段东[1] ZHOU Chunyan;DUAN Dong(The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院,重庆400016

出　　处：《现代肿瘤医学》2021年第6期1062-1066,共5页Journal of Modern Oncology

基　　金：重庆市自然科学基金(面上项目)(编号:cstc2019jcyj-msxmX0327)。

摘　　要：甲状腺癌是内分泌系统最常见的恶性肿瘤,近年来其发病率在世界范围内呈上升趋势,虽然总体治愈率高,但局部复发或远处转移也较常见,另有部分患者因肿瘤组织分化低,疾病进展较快而死亡。免疫反应和炎症反应在肿瘤的发生、发展中起着重要的作用,研究表明外周血中某些炎性细胞的数目及其比值是恶性肿瘤的重要预后因子,如血小板、中性粒细胞、淋巴细胞、单核细胞等。本文就外周血血小板/淋巴细胞比值(PLR)、中性粒细胞/淋巴细胞比值(NLR)、系统免疫炎症指数(SII)、淋巴细胞/单核细胞比值(LMR)及C反应蛋白(CRP)在甲状腺癌中的应用进展作一综述,旨在为甲状腺癌的综合诊疗提供更全面的参考。Thyroid cancer is the most common malignant tumor of endocrine system.Its incidence rate has been increasing worldwide in recent years.Although the prognosis of most patients is good,local recurrence or distant metastasis is also common.And some of them die due to low cancer differentiation and rapid disease progression.Immune response and inflammatory response play an important role in the occurrence and development of tumors.Studies have shown that the number and ratio of some inflammatory cells in peripheral blood are important prognostic factors of cancer,such as platelets,neutrophils,lymphocytes,monocytes,etc.This paper reviews the application of PLR,NLR,SII,LMR and CRP in thyroid cancer,in order to provide a more comprehensive reference for the comprehensive diagnosis and treatment of thyroid cancer.

关 键 词：甲状腺癌 血小板/淋巴细胞比值 中性粒细胞/淋巴细胞比值 系统免疫炎症指数 淋巴细胞/单核细胞比值 C反应蛋白 

分 类 号：R736.1[医药卫生—肿瘤]